Physician profile
Daniel Mekasha
NPI 1003937798
$3,696.09
in general payments reported to CMS, 2019-2025
15 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,155 · 2023: $123 · 2024: $275 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $503 · Education: $37.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $503.36 |
| Education | $37.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acelrx Pharmaceuticals, INC. | $3,013.26 | 2019 | |
| Boston Scientific Corporation | $148.04 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Ucb, INC. | $79.01 | 2023-2025 | Briviact |
| Emd Serono, INC. | $76.26 | 2023-2024 | Mavenclad |
| Pfizer INC. | $60.36 | 2024 | |
| Abbvie INC. | $55.84 | 2024-2025 | |
| Pacira Pharmaceuticals Incorporated | $39.69 | 2024-2025 | Exparel, Iovera, Zilretta |
| Lilly USA, LLC | $38.29 | 2024 | Emgality |
| Merck Sharp & Dohme LLC | $37.90 | 2023-2024 | Bridion |
| Lundbeck LLC | $30.89 | 2025 | Vyepti |
| Alnylam Pharmaceuticals INC. | $27.17 | 2023 | Amvuttra |
| Eisai INC. | $26.72 | 2025 | |
| Sk Life Science, INC. | $24.14 | 2023 | |
| Avanos Medical | $19.53 | 2019 | |
| Medtronic, INC. | $18.99 | 2024 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mekasha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.